文献速递临床试验与 GCP真实世界研究与卫生经济

糖尿病远程医疗地中海饮食(DiaTeleMed)研究:评估2型糖尿病患者个性化饮食管理的完全远程随机临床试验研究方案

Diabetes Telemedicine Mediterranean Diet (DiaTeleMed) Study: study protocol for a fully remote randomized clinical trial evaluating personalized dietary management in individuals with type 2 diabetes.
PubMed 文献 · Trials · 2024-07-25

DiaTeleMed研究是一项完全远程随机临床试验,纳入血糖控制中等的2型糖尿病患者(HbA1c 6.0%至8.0%),随机等额分配至个性化饮食组、标准化行为干预组和常规护理对照组(每组85例,共255例),主要比较各干预对血糖波动平均幅度(MAGE)的影响,测量在基线、3个月和6个月进行。

要点

  • 研究纳入HbA1c 6.0%至8.0%的2型糖尿病患者,随机分为个性化组、标准化组和常规护理组,每组85例。
  • 所有参与者均接受地中海饮食等热量营养素目标及6个月内14次干预接触。
  • 个性化组在标准化干预基础上增加餐后血糖反应实时反馈,主要结局为血糖波动平均幅度(MAGE)。

核心结论

  • DiaTeleMed研究旨在通过确定行为咨询和个性化营养建议对2型糖尿病患者血糖控制的贡献,填补精准营养领域的空白。
  • 研究的完全远程方法允许在人群层面可扩展地创新提供个性化饮食建议。

研究设计与样本

  • 完全远程随机临床试验,纳入21至80岁、血糖控制中等(HbA1c 6.0%至8.0%)且仅靠生活方式或生活方式加二甲双胍管理的2型糖尿病患者。
  • 参与者等额随机分配(n=255,每组n=85)至个性化组、标准化组或常规护理对照组(UCC)。
  • 测量在0(基线)、3和6个月进行,主要结局比较各干预对血糖波动平均幅度(MAGE)的影响。

关键数值与推荐

  • 所有参与者接受符合地中海饮食指南的等热量能量和宏量营养素目标,并在6个月内接受14次干预接触(前4次每周1次,随后10次每两周1次)以覆盖糖尿病自我管理教育。
  • 常规护理对照组前4次干预接触通过同步视频会议进行,随后提供教育视频链接。
  • 标准化组接受与常规护理对照组相同的教育内容并遵循相同时间表,但所有干预接触均通过同步视频会议进行,辅以基于社会认知理论(SCT)的行为咨询,并使用移动应用程序对计划餐食进行饮食自我监测,实时反馈卡路里和宏量营养素。
  • 个性化组接受标准化干预的所有要素,并额外获得对记录到移动应用程序中的餐食和零食的预测餐后血糖反应(PPGR)的实时反馈。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Diabetes Telemedicine Mediterranean Diet (DiaTeleMed) Study is a fully remote randomized clinical trial evaluating personalized dietary management in individuals with type 2 diabetes (T2D). The study aims to test the efficacy of a personalized behavioral approach for dietary management of moderately controlled T2D, versus a standardized behavioral intervention that uses one-size-fits-all dietary recommendations, versus a usual care control (UCC). The primary outcome will compare the impact of each intervention on the mean amplitude of glycemic excursions (MAGE). METHODS: Eligible participants are between 21 and 80 years of age diagnosed with moderately controlled T2D (HbA1c: 6.0 to 8.0%) and managed on lifestyle alone or lifestyle plus metformin. Participants must be willing and able to attend virtual counseling sessions and log meals into a dietary tracking smartphone application (DayTwo), and wear a continuous glucose monitor (CGM) for up to 12 days. Participants are randomized with equal allocation (n = 255, n = 85 per arm) to one of three arms: (1) Personalized, (2) Standardized, or (3) UCC. Measurements occur at 0 (baseline), 3, and 6 months. All participants receive isocaloric energy and macronutrient targets to meet Mediterranean diet guidelines, in addition to 14 intervention contacts over 6 months (4 weekly then 10 biweekly) to cover diabetes self-management education. The first 4 UCC intervention contacts are delivered via synchronous videoconferences followed by educational video links. Participants in Standardized receive the same educational content as those in the UCC arm, following the same schedule. However, all intervention contacts are conducted via synchronous videoconferences, paired with Social Cognitive Theory (SCT)-based behavioral counseling, plus dietary self-monitoring of planned meals using a mobile app that provides real-time feedback on calories and macronutrients. Participants in the Personalized arm receive all elements of the Standardized intervention, in addition to real-time feedback on predicted post-prandial glycemic response (PPGR) to meals and snacks logged into the mobile app. DISCUSSION: The DiaTeleMed Study aims to address an important gap in the current landscape of precision nutrition by determining the contributions of behavioral counseling and personalized nutrition recommendations on glycemic control in individuals with T2D. The fully remote methodology of the study allows for scalability and innovative delivery of personalized dietary recommendations at a population level. TRIAL REGISTRATION: ClinicalTrials.gov NCT05046886. Registered on September 16, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Berube LT, Popp CJ, Curran M, et al. Diabetes Telemedicine Mediterranean Diet (DiaTeleMed) Study: study protocol for a fully remote randomized clinical trial evaluating personalized dietary management in individuals with type 2 diabetes. Trials. 2024. PMID: 39049121. doi:10.1186/s13063-024-08337-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。